NEA closes 14th fund with $2.6B committed capital

Wednesday, July 25, 2012 02:18 PM

New Enterprise Associates (NEA), a global venture capital firm that heavily invests in biopharma, healthcare services and medical device sectors, has officially closed its 14th fund with $2.6 billion in total committed capital. The fund, one of the largest venture funds ever raised, brings NEA's total committed capital to more than $13 billion across all funds.

"NEA is deeply grateful for the continued support of many longtime limited partners, as well as some new ones, who believe that a diversified, global strategy is the path forward for venture capital," said Peter Barris, managing general partner, NEA. "Our industry has been profoundly transformed in recent years, and a new model has quietly gained traction where more dollars are being committed to large funds that are global and diversified in nature."

Today the 10 largest venture capital firms account for nearly one-third of dollars coming into the venture industry, with the concentration of capital doubling over the last decade as the overall VC market contracts. This new fund marks NEA's third consecutive $2.5-billion-plus fund, a reflection of the firm's scale and increasingly global focus.

"The venture capital ecosystem needs both large and small firms to thrive," said Barris. "But companies are scaling earlier and faster than ever before in a highly competitive global landscape, and they need partners with a global footprint and deep pockets to succeed."

First led into emerging markets by its portfolio companies, NEA now has affiliate offices in India and China and investing activities across four continents. The composition of NEA's limited partner group has also become more global. Dollars from international investors are up 10% over the firm's 10th fund, a 2000-vintage fund that coincided with NEA's expanded focus on emerging markets.

Consistent with its strategy in recent funds, NEA will continue to invest in information technology, healthcare and energy technology. Within the information technology sector, areas of particular interest include enterprise software and systems, education, consumer technology and digital media. The firm's healthcare investing strategy continues to focus on opportunities in the biopharma, healthcare services and medical device sectors.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs